SCHEMBL282583

SCHEMBL282583

CC(C)(C)[Si](C)(C)Oc1ccc(B(O)O)cc1

nearest known ligand 0.50

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
CA1 P00915 7/20 0.50
CA2 P00918 4/20 0.50
ENPP2 Q13822 2/20 0.50
PREP P48147 4/20 0.43
CA12 O43570 4/20 0.41
CA9 Q16790 4/20 0.41
LPL P06858 2/20 0.40
LIPG Q9Y5X9 2/20 0.40
TSHR P16473 1/20 0.40
MGLL Q99685 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL932807 0.84 CA1 (0.52) CA1CA2ENPP2PREPCA12
SCHEMBL29954502 0.84 CA1 (0.52) CA1CA2ENPP2PREPCA12
SCHEMBL6763899 0.83 PREP (0.53) CA1CA2PREPCA12CA9
SCHEMBL2892021 0.81 PREP (0.43) CA1PREPCA12CA9
SCHEMBL9988018 0.81 CA1 (0.38) CA1CA2ENPP2PREPCA12
SCHEMBL1881020 0.79 ENPP2 (0.56) CA1CA2ENPP2CA12CA9
SCHEMBL173365 0.78 PREP (0.49) CA1PREPCA12CA9TSHR
SCHEMBL23491348 0.77 PREP (0.57) CA1PREPCA12CA9
SCHEMBL20358470 0.77 PREP (0.49) CA1PREPCA12CA9TSHR
SCHEMBL614621 0.75 PREP (0.47) CA1CA2PREPCA12CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 331 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250194617-A1 Materials and Methods for Extending Shelf-Life of Foods JP LABORATORIES, INC. 2025-06-19 US claimed
US-20250169514-A1 Materials and Methods for Extending Shelf-Life of Foods JP LABORATORIES, INC. 2025-05-29 US claimed
CN-119175113-B Terephthalic acid hydrogenation catalyst and preparation method and application thereof 临朐恒辉新材料有限公司 2025-01-21 CN claimed
CN-119175113-A Terephthalic acid hydrogenation catalyst and preparation method and application thereof 临朐恒辉新材料有限公司 2024-12-24 CN claimed
US-20230380457-A1 Materials and Methods for Extending Shelf-Life of Foods JP LABORATORIES, INC. 2023-11-30 US claimed
EP-4280882-A2 MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS JP LABORATORIES, INC. (US) 2023-11-29 EP claimed
US-20230363426-A1 Materials and Methods for Extending Shelf-Life of Foods JP LABORATORIES, INC. 2023-11-16 US claimed
US-11793220-B2 Materials and methods for extending shelf-life of foods JP LABORATORIES, INC. (US) 2023-10-24 US claimed
CN-116916755-A Materials and methods for extending the shelf life of food products JP实验室公司 2023-10-20 CN claimed
CN-114516927-B Functionalized polystyrene polymer and preparation method and application thereof 华东理工大学 2023-03-10 CN claimed
US-20220264914-A1 MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS JP LABORATORIES, INC. 2022-08-25 US claimed
WO-2022159439-A2 MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS JP LABORATORIES, INC. (US) 2022-07-28 WO claimed
US-20220225647-A1 MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS JP LABORATORIES, INC. 2022-07-21 US claimed
US-20220225646-A1 MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS JP LABORATORIES, INC. 2022-07-21 US claimed
CN-114516927-A Functionalized polystyrene polymer and preparation method and application thereof 华东理工大学 2022-05-20 CN claimed
US-20250388575-A1 HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE HALDA THERAPEUTICS OPCO INC (US) 2025-12-25 US disclosed
US-20250388605-A1 HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE HALDA THERAPEUTICS OPCO INC (US) 2025-12-25 US disclosed
US-5039673-A Anticoagulants, bronchodilators, vasodilators GLAXO GROUP LIMITED (GB) 1991-08-13 US disclosed
EP-0297855-A1 Aminocyclopentyl ethers and their preparation and pharmaceutical formulation GLAXO GROUP LIMITED (GB) 1989-01-04 EP disclosed
EP-0296802-A1 Aminocyclopentyl ethers and their preparation and pharmaceutical formulation GLAXO GROUP LIMITED (GB) 1988-12-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250388575-A1 HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS, CBR1 CA1 269/4885CA2 74/4885ENPP2 2482/4885
US-20250388605-A1 HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE BRD4, BRDT, BICRA CA1 2137/4885CA2 1397/4885ENPP2 3551/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.